Multiple Myeloma an incurable disease, but I have spent the last 25 years in remission using a blend of conventional oncology and evidence-based nutrition, supplementation, and lifestyle therapies from peer-reviewed studies that your oncologist probably hasn't told you about.
Click the orange button to the right to learn more about what you can start doing today.
When is a myeloma relapse not a relapse? No, this is not a dad joke. I’m serious. Just because a MM patient’s number (s) increase does not mean they have to rush to begin a different treatment. A relapse is not a “clinical relapse” if it is a “biochemical relapse.”
Do not be surprised if your oncologist wants to begin treatment as soon as one or more of a MM survivor’s blood work changes. This change could be one value.
I’m not saying that you should not begin a different treatment regimen. I’m simply saying that chemo cocktails can be exhausting. Even damaging to the patient. MM patients and caregivers frequently are looking for the best time for a break or therapy vacation.
I’m saying that a biochemical relapse could be the time to give the MM patient a therapy vacation. Without sacrificing too much. And gaining time to let your body heal, perhaps letting your blood levels- red, white blood cells, and platelets- return to normal.
As always, ask your oncologist if you are experiencing a biochemical relapse and not a clinical relapse. And then ask your oncologist if you could take a therapy vacation until you reach a clinical relapse.
The treatment of MM has come a long way since my diagnosis in early 1994. I don’t think diagnostic testing was sensitive enough back then to distinguish between biochemical and clinical relapses.
Email me at David.PeopleBeatingCancer@gmail.com to learn more about managing your MM with both conventional and non-conventional MM therapies.
Thank you,
David Emerson
The median time for a biochemical relapse (BR) in multiple myeloma (MM) to progress to a clinical relapse (CR) is approximately 5 months.
However, the duration of BR can vary significantly; some patients may progress to CR within months, while about 20-25% of patients may remain in biochemical relapse for several years without progressing to symptomatic disease.
Each patient’s disease biology and response to treatment are unique, leading to a wide range of times to progression.
Factors like the presence of high-risk genetic abnormalities at diagnosis can influence the pattern and aggressiveness of relapse.
The timing of treatment initiation following a biochemical relapse is a subject of ongoing research, with some studies suggesting benefits to starting treatment earlier rather than waiting for clinical symptoms to develop.
Historically, the aim was to delay treatment until clinical relapse to spare patients from early side effects, as early rescue options were limited.
Recent evidence suggests that initiating treatment after a biochemical relapse, rather than waiting for a clinical relapse, may improve patient outcomes.